Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kite Pharma Inc (Kite Pharma), a subsidiary of Gilead Sciences Inc, is a biopharmaceutical company that discovers and develops cancer immunotherapy products. Kite Pharma offers profucts including like Chimeric Antigen Receptors(CAR), KTE-C19 DLBCL, PMBCL, TFL (ZUMA-1); Chemo Refractory Diffuse Large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), KTE-C19 MCL (ZUMA-2); Relapsed/Refractory Mantle Cell Lymphoma (MCL), KTE-C19 Adult and Pediatric ALL (ZUMA-3, ZUMA-4); Acute Lymphoblastic Leukemia (ALL), Axicabtagene ciloleucel; 2L+ high-risk follicular lymphoma, Axicabtagene ciloleucel; 1L high-risk large B-cell lymphoma, Axicabtagene ciloleucel; 2L large B-cell lymphoma outpatient, Brexucabtagene autoleucel; Basket (rare B-cell malignancies). It carries out the Kite External Research Program service. The company has operations across the UK, the Netherlands and the US. Kite Pharma is headquartered in Santa Monica, California, the US.
Headquarters
United States of America
Address
2400 Broadway, Santa Monica, California, 90404
Website
www.kitepharma.com
Telephone
1 310 8249999
Industry
Pharmaceuticals and Healthcare
Kite Pharma Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Chimeric Antigen Receptors(CAR) | Kite External Research Program |
| KTE-C19 DLBCL, PMBCL, TFL (ZUMA-1): | |
| Chemo Refractory Diffuse Large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In August, the company entered into an agreement to acquire Interius BioTherapeutics for US$350 million. |
| 2024 | Plans/Strategy | In September, the company announced its plans to sell a 50% stake in Fosun Kite Biotechnology to Shanghai Fosun Pharmaceutical Industrial Development. |
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with Arcellx for CART-ddBCMA to include lymphomas. |
Competitor Comparison
| Key Parameters | Kite Pharma Inc | Fate Therapeutics Inc | Actinium Pharmaceuticals Inc | BioMed Valley Discoveries Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Santa Monica | San Diego | New York City | Kansas City |
| State/Province | California | California | New York | Missouri |
| No. of Employees | - | 161 | 25 | - |
| Entity Type | Private | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shelby Geyer | Head - Finance; Vice President | Senior Management | 2023 | - |
| Priti Hegde | Global Head of Kite Research; Senior Vice President | Senior Management | 2023 | - |
| Dominique Tonelli | Global Head of Medical Affairs; Vice President | Senior Management | 2017 | - |
| Sarah Stephens | Executive Director-Public Affairs | Senior Management | 2025 | - |
| Kevin Cognetti | Vice President - Corporate Strategy and Planning. | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer